(Q44738504)

5 December 2017

title

Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis (English)

1 reference

5 December 2017

0 references

0 references

1 reference

2

1 reference

5 December 2017

Eriksson T

1

1 reference

5 December 2017

Turesson I

3

1 reference

5 December 2017

Waage A

4

1 reference

5 December 2017

Don BR

5

1 reference

5 December 2017

Vu J

6

1 reference

5 December 2017

Scheffler M

7

1 reference

5 December 2017

Kaysen GA

8

1 reference

5 December 2017

publication date

1 December 2003

1 reference

Journal of Pharmacy and Pharmacology

5 December 2017

published in

1 reference

5 December 2017

volume

55

1 reference

5 December 2017

issue

12

1 reference

5 December 2017

page(s)

1701-1706

1 reference

Thalidomide: current and potential clinical applications

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1211%2F0022357022241

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357022241

Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357022241

Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357022241

Clinical pharmacology of thalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357022241

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357022241

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357022241

Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357022241

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357022241

Inflammation and cardiovascular risk in dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357022241

Population pharmacokinetics. Theory and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357022241

C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357022241

21 January 2018

Identifiers

DOI

10.1211/0022357022241

1 reference

5 December 2017

1 reference